Editas Medicine Inc (EDIT NASDAQ) stock market data APIs
$2.4374
-0(-0%)
as of December 9, 2025
Try our APIs with
free plan!
Editas Medicine Inc Financial Data Overview
Price chart is built with
Anychart
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Prev. Close
2.4374
Open
2.4337
High
2.4985
Low
2.3719
52 wk Range
0.9101-4.5372
Market Cap
236 M
Shares Outstanding
97 619 K
Revenue
46 383 K
EPS
-0.28
Beta
2.44
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Editas Medicine Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Editas Medicine Inc data using free add-ons & libraries
Get Editas Medicine Inc Fundamental Data
Editas Medicine Inc Fundamental data includes:
- Net Revenue: 46 383 K
- EBITDA: -112 038 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-10
- EPS/Forecast: -0.3
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Editas Medicine Inc News
New
Editas (EDIT) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool. DATE Wednesday, August 7, 2024 at 12:03 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Gilmore O’NeillChief Medical Officer — Baisong MeiChief Financial O...
NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies
Novo Nordisk NVO reported disappointing top-line data from the two-year primary analysis of two late-stage studies evaluating Rybelsus (oral semaglutide 14 mg) for early-stage symptomatic Alzheimer’...
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
Biogen BIIB announced the signing of a research collaboration agreement with privately held Dayra Therapeutics to discover and develop oral macrocyclic peptides for priority targets in immunological c...
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
AstraZeneca AZN announced that the FDA has approved its oral, selective MEK inhibitor, Koselugo (selumetinib), for expanded use. The drug is now indicated to treat symptomatic, inoperable plexiform ne...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
